Homology Medicines, Inc. (FIXX):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C5327)
◆英語タイトル:Homology Medicines, Inc. (FIXX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C5327
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年9月
◆ページ数:32
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥26,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥52,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥78,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Homology Medicines, Inc. (Homology Medicines) is a pre-clinical stage biopharmaceutical company engaged in translating gene editing and gene therapy into novel treatment for patients suffering from rare genetic diseases. It offers HMI-102 product, which is in clinical stage for the treatment of Phenylketonuria (PKU). The company’s gene editing technology is used in DNA repairs, and gene therapy approach along with AAVHSC vectors delivers a functional gene to treat monogenic diseases in the liver, lung, none marrow and eye. Genetic medicines are used for treating newborn and pediatric patients. Homology Medicines is headquartered in Bedford, Massachusetts, the US.

Homology Medicines, Inc. (FIXX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Homology Medicines, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Homology Medicines, Inc., Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Homology Medicines, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Homology Medicines, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Homology Medicines, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Homology Medicines, Inc., Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Homology Medicines Raises USD83.5 Million in Series B Financing 10
Homology Medicines Raises USD43.5 Million in Series A Financing Round 12
Homology Medicines Raises USD23 Million in Venture Financing 14
Partnerships 15
Homology Medicines Enters into Agreement with Novartis 15
Licensing Agreements 16
Homology Medicines Amends its Licensing Agreement with California Institute of Technology 16
City of Hope Signs Licensing Agreement with Homology Medicines 17
Equity Offering 18
Homology Medicines Raises USD165.6 Million in IPO 18
Homology Medicines, Inc. – Key Competitors 20
Homology Medicines, Inc. – Key Employees 21
Homology Medicines, Inc. – Locations And Subsidiaries 22
Head Office 22
Recent Developments 23
Financial Announcements 23
Aug 13, 2018: Homology Medicines reports second quarter 2018 financial results 23
May 14, 2018: Homology Medicines Announces First Quarter 2018 Financial Results 25
Corporate Communications 27
Mar 15, 2018: Homology Medicines Appoints Mary Thistle to Board of Directors 27
Jan 17, 2018: Homology Medicines Appoints Matthew R. Patterson to Board of Directors 28
Apr 04, 2017: Homology Medicines Appoints Brad Smith as Chief Financial Officer 29
Product News 30
Jul 16, 2018: Homology Medicines announces peer-reviewed publication demonstrating efficient and precise in vivo gene editing capabilities of nuclease-free technology platform 30
Mar 01, 2018: Homology Medicines Announces Peer-Reviewed Publication Indicating Low Prevalence of Pre-existing Neutralizing Antibodies to its Human-Derived AAVHSC Vectors 31
Appendix 32
Methodology 32
About GlobalData 32
Contact Us 32
Disclaimer 32

List of Tables
Homology Medicines, Inc., Pharmaceuticals & Healthcare, Key Facts, 2017 2
Homology Medicines, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Homology Medicines, Inc., Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Homology Medicines, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Homology Medicines, Inc., Deals By Therapy Area, 2012 to YTD 2018 8
Homology Medicines, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Homology Medicines Raises USD83.5 Million in Series B Financing 10
Homology Medicines Raises USD43.5 Million in Series A Financing Round 12
Homology Medicines Raises USD23 Million in Venture Financing 14
Homology Medicines Enters into Agreement with Novartis 15
Homology Medicines Amends its Licensing Agreement with California Institute of Technology 16
City of Hope Signs Licensing Agreement with Homology Medicines 17
Homology Medicines Raises USD165.6 Million in IPO 18
Homology Medicines, Inc., Key Competitors 20
Homology Medicines, Inc., Key Employees 21

List of Figures
Homology Medicines, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Homology Medicines, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Homology Medicines, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Homology Medicines, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Homology Medicines, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Homology Medicines, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Homology Medicines, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Homology Medicines, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Homology Medicines, Inc. (FIXX):製薬・医療:M&Aディール及び事業提携情報(Homology Medicines, Inc. (FIXX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆